Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study.

Among the 1846 patients in the HEMO Study, chronic high-flux dialysis did not significantly affect the primary outcome of the all-cause mortality (ACM) rate or the main secondary composite outcomes, including the rates of first cardiac hospitalization or ACM, first infectious hospitalization or ACM, first 15% decrease in serum albumin levels or ACM, or all non-vascular access-related hospitalizations. The high-flux intervention, however, seemed to be associated with reduced risks of specific cardiac-related events. The relative risks (RR) for the high-flux arm, compared with the low-flux arm, were 0.80 [95% confidence interval (CI), 0.65 to 0.99] for cardiac death and 0.87 (95% CI, 0.76 to 1.00) for the composite of first cardiac hospitalization or cardiac death. Also, the effect of high-flux dialysis on ACM seemed to vary, depending on the duration of prior dialysis. This report presents secondary analyses to further explore the relationship between the flux intervention and the duration of dialysis with respect to various outcomes. The patients were stratified into a short-duration group and a long-duration group, on the basis of the mean duration of dialysis of 3.7 yr before randomization. In the subgroup that had been on dialysis for >3.7 yr, randomization to high-flux dialysis was associated with lower risks of ACM (RR, 0.68; 95% CI, 0.53 to 0.86; P = 0.001), the composite of first albumin level decrease or ACM (RR, 0.74; 95% CI, 0.60 to 0.91; P = 0.005), and cardiac deaths (RR, 0.63; 95% CI, 0.43 to 0.92; P = 0.016), compared with low-flux dialysis. No significant differences were observed in outcomes related to infection for either duration subgroup, however, and the trends for beneficial effects of high-flux dialysis on ACM rates were considerably weakened when the years of dialysis during the follow-up phase were combined with the prestudy years of dialysis in the analysis. For the subgroup of patients with <3.7 yr of dialysis before the study, assignment to high-flux dialysis had no significant effect on any of the examined clinical outcomes. These data suggest that high-flux dialysis might have a beneficial effect on cardiac outcomes. Because these results are derived from multiple statistical comparisons, however, they must be interpreted with caution. The subgroup results that demonstrate that patients with different durations of dialysis are affected differently by high-flux dialysis are interesting and require further study for confirmation.

[1]  B. Descamps-Latscha,et al.  Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in-vitro haemodialysis. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  H. Müller,et al.  Levels of alpha1 acid glycoprotein and ceruloplasmin predict future albumin levels in hemodialysis patients. , 2001, Kidney international.

[3]  C. Tetta,et al.  Pyrogen retention by highly permeable synthetic membranes during in vitro dialysis. , 2001, Artificial organs.

[4]  S. Nishi,et al.  Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. , 1997, Kidney international.

[5]  A. Kaplan,et al.  Dialysate protein losses with bleach processed polysulphone dialyzers. , 1995, Kidney international.

[6]  H. F. Woods,et al.  Nephrology Dialysis Transplantation Improved Outcome for Haemodialysis Patients Treated with High-flux Membranes , 2022 .

[7]  B. Pereira,et al.  Hematocrit Level Associated Mortality in Hemodialysis Patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610–619, 1999 , 2000, Seminars in dialysis.

[8]  Johanna T Dwyer,et al.  Effect of dialysis dose and membrane flux in maintenance hemodialysis. , 2002, The New England journal of medicine.

[9]  M. Schambelan,et al.  Leptin, body composition, and indices of malnutrition in patients on dialysis. , 1998, Journal of the American Society of Nephrology : JASN.

[10]  A. Cheung,et al.  Single Compartment Models for Evaluating β2-Microglobulin Clearance During Hemodialysis , 1997, ASAIO journal.

[11]  B. Maldague,et al.  Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. , 1991, Kidney international.

[12]  W. Hörl,et al.  Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. , 1995, Journal of the American Society of Nephrology : JASN.

[13]  B. Jaber,et al.  Effect of formaldehyde/bleach reprocessing on in vivo performances of high-efficiency cellulose and high-flux polysulfone dialyzers. , 1998, Journal of the American Society of Nephrology : JASN.

[14]  N. Levin,et al.  Improvement of plasma lipoprotein profiles during high-flux dialysis. , 1993, Journal of the American Society of Nephrology : JASN.

[15]  L. Agodoa,et al.  United States Renal Data System (USRDS). , 2000, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[16]  R. Tibshirani,et al.  Monographs on statistics and applied probability , 1990 .

[17]  D. Marcelli,et al.  Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. , 1999, Kidney international.

[18]  R. Lindsay,et al.  A hypothesis: the protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. , 1989, American Journal of Kidney Diseases.

[19]  J. Kusek,et al.  Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. , 2001, Kidney international.

[20]  J. Uribarri,et al.  Middle molecule clearance does not influence protein intake in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  R. Wolfe,et al.  Relationship of dialysis membrane and cause-specific mortality. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  J. Hornberger,et al.  A multivariate analysis of mortality and hospital admissions with high-flux dialysis. , 1992, Journal of the American Society of Nephrology : JASN.

[23]  R. Wolfe,et al.  Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  J. Bergstrom Mechanisms of uremic suppression of appetite. , 1999, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[25]  A. Cheung,et al.  Effects of Hemodialyzer Reuse on Clearances of Urea and β2-Microglobulin , 1999 .

[26]  P. Södersten,et al.  Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. , 1996, Journal of the American Society of Nephrology : JASN.

[27]  E G Lowrie,et al.  The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. , 1993, The New England journal of medicine.

[28]  W. Hörl,et al.  Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Greene,et al.  Anthropometrically estimated total body water volumes are larger than modeled urea volume in chronic hemodialysis patients: effects of age, race, and gender. , 2003, Kidney international.

[30]  John T Daugirdas,et al.  Dialyzer Performance in the HEMO Study:In Vivo K0A and True Blood Flow Determined from a Model of Cross-Dialyzer Urea Extraction , 2004, ASAIO journal.

[31]  R. Vanholder,et al.  Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. , 1991, Kidney international.

[32]  George A Kaysen,et al.  Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. , 2002, Kidney international.

[33]  T A Ikizler,et al.  Amino acid and albumin losses during hemodialysis. , 1994, Kidney international.

[34]  D.,et al.  Regression Models and Life-Tables , 2022 .

[35]  R. Marcén,et al.  Effect of different membranes on amino-acid losses during haemodialysis. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.